For important risk and disclaimer information, Click here.
Doug Jendras | Managing Director | |
(203) 501-7667 |
Overview
IP3 Technologies is seeking $10 million in equity/debt to out-license patent protected intellectual property (IP) assets worldwide and to fund optimization of the intellectual property portfolio.
IP3 uses a diversified, agnostic market sector criteria for intellectual property
Current portfolio includes wide neck packaging, covert nano barcode, high temperature heat and fire insulation, analytical identification system, antimicrobial additive and anti-infective
IP3 negotiations currently ongoing to onboard a world leading IP licensing team
IP risks are mitigated by specialist IP & legal insurance and third-party royalty audits
Worldwide royalty payments made for the use of intellectual property in 2023 reached US$528 billion.
Intellectual property makes up 90% of the value of S&P 500 (approx. $35 trillion).
PWC audit of IP3 revenue model and business methodology exceeds $500M valuation.
Opportunity
Royalty income, including royalty-related income and intellectual property income, has an attractive risk-return profile
Limited exposure to the operational risks of the licensee business while maintaining benefits of revenue growth of the product/technology
Royalty income is typically revenue-based and able to benefit from inflationary environments as they are neither capital intensive nor exposed to input costs from production
Long term royalty income generation due to favorable patent protection laws
Royalty income should be immune from risks and fluctuations in bond and equity markets
Ability to capitalize the individual royalty streams by selling to pension and sovereign wealth funds
Strategy
Intellectual property origination focused on large volume/value markets in diverse sectors such as Military and Aerospace, Packaging and Global Supply Chains, Electric Vehicles, Batteries, Healthcare and Pharmaceutical
Agnostic market sector criteria for intellectual property ensures risk diversification
Innovative products & technologies developed are ready for commercialization by a licensee with minimal capital investment
The out-licensing program primarily targets major corporations to ensure high quality revenue streams
Consistently replenish a diversified portfolio to generate new revenue streams
Layering of current & future individual royalty streams has a compounding effect
Solution
IP asset portfolios include patents, patent applications and trade secret technologies
Current portfolio includes wide neck packaging, covert nano barcode, high temperature heat & fire insulation, analytical identification system, antimicrobial additive and anti-infective
Outsourced business model to minimize capital expenditures and staffing requirements
Management
Henry Guy Stevens – CEO, Director
A 35+ year career in research & management, with over 200 patents granted for products spanning sectors from logistics & packaging to software & consumer products and their relevant licensing. Has more recently undertaken the origination and optimization of the intellectual property pipeline for IP3. Previously managing commercial interests in multiple jurisdictions including United Kingdom, Middle East, Bermuda, SE Asia and USA.
Jim Elgart – CFO, Director
Founded MarathonCFO, an outsourced accounting and fractional CFO firm based in Boston. Has 25+ years of experience as a financial professional helping companies scale and grow their financial infrastructure and design and execute financial strategies. Has been the “point” on multiple funding and liquidity transactions and has established the financial infrastructure for several private funds.
Specific Risks
- Patent Litigation – intellectual property (IP) insurance typically serves two purposes — it can help companies cover litigation costs related to the enforcement or defense of patents, trademarks or copyrights, and it can help protect policyholders from patent infringement claims brought against them
- Patent Infringement – a company producing/selling a product which infringes on the rights granted under the patent. Legal action is necessary beginning with cease-and-desist letters or sign a license progressing to court action
- Unpaid Royalties – the understating of actual production/sales to reduce royalty payments. Royalty agreements have clauses allowing licensors to use 3rd party auditors to check production/sales records and companies provide the onsite audit services
- Regulatory (EPA/FDA) approvals may take longer than expected
- Licensing negotiations may take longer than projected
- Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment